The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC).
 
Samuel Ejadi
No Relationships to Disclose
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
A. Oliver Sartor
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Biscayne Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Sanofi; Teva; Tokai Pharmaceuticals
Research Funding - Bayer (Inst); Endocyte (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst); Sotio (Inst)
 
Andrew Habbe
No Relationships to Disclose
 
Binh Nguyen
No Relationships to Disclose
 
Anthony W. Tolcher
Stock and Other Ownership Interests - Symphony Evolution
Consulting or Advisory Role - AbbVie; Adnexus; Ambit BioSciences; AP Pharma; Aragon Pharmaceuticals; ARIAD; ArQule; Asana Biosciences; Astellas Pharma; Astex Pharmaceuticals; AVID Radiopharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; BioMed Valley Discoveries; Blend Therapeutics; Bristol-Myers Squibb; Celator; Clovis Oncology; Curis; Dicerna; Eisai; Emergent BioSolutions; Heron; Janssen; Johnson & Johnson; Lilly; MedImmune; Merck Sharp & Dohme; Merus; Micromet; Nanobiotix; Nektar; Neumedicines; Novartis (I); Oncogenex; Pfizer; Pharmacyclics; Pierre Fabre; ProNAi; Proximagen; Symphony Evolution; Vaccinex; Valent Technologies; Zyngenia; Zyngenia